Cavinton administration in hypertensive encephalopathy


Cite item

Full Text

References

  1. Суслина З. А., Танашян М. М. и др. Кавинтон в лечении больных с острыми и хроническими сосудистыми заболеваниями головного мозга. Фарматека 2004; 14: 99-104.
  2. Ощепкова Е. В. Гипертоническая энцефалопатия: возможности профилактики. Справочник поликлин. врача 2003; 3: 1-4.
  3. Карлов А. В. Применение препарата Кавинтон Форте у больных с дисцикуляторной энцефалопатией. Рус. мед. журн. 12 (10): 626-628.
  4. Backhauss С., Karkoutly С., Welsch M. et аl. A mouse model of focal cerebral ischemia for screening neuroprotective drug effects. J. Pharmacol. Toxicol. Meth. 1992; 27: 27-32.
  5. Balestreri R., Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-430.
  6. Bhardwaj A., Northington F. J., Koehler R. C. et al. Adenosine modulates N-methyl-D-aspartate-stimulated hippocampal nitric oxide production in vivo. Stroke 1995; 26: 1627-1633.
  7. Blaha L., Erzigkeit H., Adamczyk A. et al. Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Hum. Psych. 1989; 4: 103-111.
  8. Blaustein M. P., Goldman W. F., Fontana G. et al. Physiological roles of the sodium-calcium exchanger in nerve and muscle. Ann. N. Y. Acad. Sci. 1991; 639: 254-274.
  9. Bliss T. V., Collingridge. G. L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993; 361: 31-39.
  10. Brodie C., Blumberg P. M., Jacobson K. A. Activation of the A2a adenosine receptor inhibits nitric oxide production in glial cells. FEES Lett. 1998; 429: 139-142.
  11. Choi D. W. Calciummediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 1988; 11: 465-469.
  12. Coleston D. M., Hindmarch I. Possible memory-enhancing properties of vinpocetine. Drug Dev. Res. 1988; 44: 191-193.
  13. Csanda E., Harcos P. Bdcsy Zs. et al. Ten years of experience with Cavinton. Drug Dev. Res. 1988; 14: 185-187.
  14. Ebi O. Open-labeled phase III clinical trials with vinpocetine in Japan. Ther. Hung. 1985; 33: 41-49.
  15. Erdo S. L., Molndr P., Bence J. Z. et al. Vinca-mine and vincanol are potent blockers of voltage-gated Na+ channels. Eur. J. Pharmacol. 1996; 314: 69-73.
  16. Erdo S. L., Ning-sheng C., Wolff J. R. et al. Vinpocetin protects against excitotoxic cell death in primary cultures of rat cerebral cortex. Eur. J. Pharmacol. 1990; 187: 551-553.
  17. Fenzl E., Apecechea M., Schaltenbrand R. et al. Long-term study concerning tolerance and efficacy of vinpocetine in elderly patients suffering from a mild to moderate organic psychosyndrome. In: Senile Dementias: Early Detection. Szerk.: Bes A. et al: John Libbey Eurotext; 1986. 580-585.
  18. Fern R., Ransom B. R., Stys P. K. et al. Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam. J. Pharmacol. Exp. Ther. 1993; 256: 1549-1555.
  19. Fredholm В. В., Lindgren E., Lindstrom N. et al. The effect of some drugs with purported antianoxic effects on veratri-dine-induced purine release from isolated rat hypothalamic synaptosomes. Acta Pharmacol. (Kbh.) 1983; 53: 236-244.
  20. George A. E., de Lean M. J., Kalnin A. et al. Leukoencephalopathy in normal and pathologic aging. II. MRI of brain lucencies. A. J. N. R. 1986; 7: 567-570.
  21. Groo D., Pdlosi E., Szporny L. Effect of vinpocetine in memory disturbances induced by different damaging agents. In: Pharmacology of cerebral ischemia. Szerk.: Krieglstein J. J. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH.; 1989.
  22. Hachinski V. C., Potter P., Merskey H. Leuko-araiosis. Arch. Neurol. 1987; 44: 21-23.
  23. Hagiwara M., Endo Т., Hidaka H. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol. 1984; 33: 453-457.
  24. Hayakawa M. Comparative efficacy of vinpocetine, pentoxifylline and nicergoline on red blood cell deformability. Arzneimittelforschung 1992; 42: 108-110.
  25. Hayakawa M. Effect of vinpocetine on red blood cell deformability in stroke patients. Arzneimittelforschung 1992; 42: 425- 427.
  26. Hindmarch L., Fuchs H.-H., Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int. Clin. Psych. 1991; 6: 31-43.
  27. Ishihara K., Katsuki H., Sugimura. M. et al. Idebenone and vinpocetine augment long-term potentiation in hippocampal scices in the guinea pig. Neuropharm. 1989; 28: 569-573.
  28. Jong G. I. de, De Vos R. A., Steur E. N. et al. Cerebrovascular hypoperfusion: a risk factor for Alzheimer's disease? Animal model and postmortem human studies. Ann. N. Y. Acad. Sci. 1997; 826: 56-74.
  29. Kakihana M., Suno M., Shibota M. et al. Protective effects of vinpocetine on experimental brain ischemia. Folia Pharmacol. Jpn. 1982; 80: 225-229.
  30. Kaneko S., Sugimura M., Inoue T. et al. Effects of several cerebroprotective drugs on NMD A channel function: evaluation using Xenopus oocytes and (3H)MK-801 binding. Eur. J. Pharmacol. 1991; 207: 119-128.
  31. King G. A. Protective effects of vinpocetine and structurally related drugs on the lethal consequences of hypoxia in mice. Arch. Int. Pharmacodyn. 1987; 286: 299-307.
  32. Kiss В., Kdr-pdti E. Vinpocetin hatasai, hatasmechanizmusa. Acta Pharm. Hung. 1996; 66: 213-224.
  33. Kovdcs L. A Cavinton hatas-mechanizniusarol. 1988; RGD: 37444/4.
  34. Krieglstein J., Rischke R. Vinpocetine increases the neuroprotective effect of adenosine in vitro. Eur. J. Pharmacol. 1991; 205: 7-10.
  35. Kuzuya F. Effects of vinpocetine on platelet aggregability and erythrocyte deformability. Geriatr. Med. 1982; 20: 151-156.
  36. Lakics V., Sebestyen M. G., Erdo S. L. Vinpocetine is a highly potent neuroprotectant against veratridine-induced cell death in primary cultures of rat cerebral cortex. Neurosci. Lett. 1995; 185: 127-130.
  37. Lauter H. "Psychologic des 20 Jahr-hunderts" Vol X., Psychiatric. Szerk.: Peters, U. H. Kindler, 1980. 637-663.
  38. Lebedeva N. V., Lobkova T. N., Ionova V. G. et al. Status of microcirculation and rheological properties of blood in patients with cerebral circulatory disorders. Klin. Med. (Mosk.). 1990; 68: 31-33.
  39. Lechner H., Schmidt R. The management of chronic cerebral ischemia. In Advances in Neurology: Chopra J. S., Jagan-nathan K., Sawhney I. M. S. International Congress Series 883, Proceedings of the XIVth World Congress of Neurology, New Delhi, India, October 22-27, 1989, Excerpta Medica, Elsevier Science Publishers B. V., 145-172.
  40. Leigh P. N., Meldrum B. S. Excitotoxiciry in ALS. Neurol. 1996; 47 (Suppl. 4): S221-S227.
  41. Lindgren S. H. S., Andersson T. L. G., Vinge E. et al. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels. Act. Physiol. Scand., 199o, 140, 209-219.
  42. Madison D. V., Malenka R. C., Nicoll R. A. Mechanisms underlying long-term potentiation of synaptic transmission. Ann. Rev. Neurosci. 1991; 14: 379-397.
  43. Manconi E., Binaghi F., Pitzus F. A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Curr. Ther. Res., 1986; 40: 702-709.
  44. Molnar P., Erdo S. L. Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons. Eur. J. Pharmacol. 1995; 273: 303-306.
  45. Molnar P., Gadl L., Horvdth C. The impairment of long-term potentiation in rats with medial septal lesion and its restoration by cognition enhancers. Neurobiol. 1994; 2: 255-266.
  46. Miyazaki M. The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by te Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiol. 1995; 46: 53-58.
  47. Nagy Z., Bonoczk P., Pdnczel Gy. et al. Cavinton review. Praxis 1996; 5: 1-6.
  48. Nagy Z., Varga P., Kovdcs L. et al. Cavinton metaanalizis. Praxis 1998; 7: 63-68.
  49. Ohta H., Nishikawa H., Kimura H. et al. Chronic cerebral hypoperfusion by permanent internal carotid ligation produces learning impairment without brain damage in rats. Neurosci. 1997; 79: 1039-1050.
  50. Oldh A. V., Balla G., Balla J. et аl. An in vitro study of the hydroxyl scavenger effect of Cavinton. Act. Pediatr. Hung. 1990; 30: 309-316.
  51. Osawa M., Maruyama S. Effects of TCV-3B (Vinpocetine) on blood viscosity in ischemic cerebrovascular diseases. Ther. Hung. 1985; 33: 7-12.
  52. Otomo E., Atarashi J., Araki G. et al. Comparison of vinpocetine with ifenprodil tartarate and di-hydroergotoxine mesylate treatment and results of long-term treatment with vinpocetine. Curr. Ther. Res. 1985; 37: 811-821.
  53. Peruzza M., De Jacobis M. A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. Adv. Ther. 1986; 3: 201-209.
  54. Rosdy В., Baldzs M., Szporny L. Biochemical effects of ethyl apovincaminate. Arzneim-Forsch. (Drug Res.), 1976; 26: 1923-1926.
  55. Rudolphi K. A., Schubert P. Modulation of neuronal and glial cell function by adenosine and neuropro-tection in vascular dementia. Behav. Brain. Res. 1997; 83: 123-128.
  56. Russell R. W., Page N. G. R. Critical perfusion of brain and retina. Brain 1983; 106: 419-434.
  57. Sauer D., Rischke R., Beck T. et al. Vinpocetine prevents ischemic cell damage in rat hippocampus. Life Sci. 1988; 43: 1733-1739.
  58. Schmid-Schonbein H., Grebe R., Teitel P. et al. Restoration of microsieve filterability of human red cells after exposure to hyperosmolarity and lactacidosis: effect of vinpocetine. Drug. Dev. Res. 1988; 14: 205-211.
  59. Sekhon L. H. S., Morgan M. K., Spence I. et al. Chronic cerebral hypoperfusion and impaired neuronal function in rats. Stroke 1994; 25: 1022-1027.
  60. Sekhon L. H. S., Morgan M. K., Spence I. et al. Chronic cerebral hypoperfusion: pathological and behavioral consequences. Neurosurg. 1997; 40: 548-556.
  61. Sekhon L. H. S., Spence I., Morgan M. K. et al. Chronic cerebral hypoperfusion inhibits calcium-induced long-term potentiation in rats. Stroke 1997; 28: 1043-1048.
  62. Schubert P., Ogata Т., Marchini С et al. Protective mechanisms of adenosine in neurons and glial cells. Ann. N. Y. Acad. Sci. 1997; 825: 1-10.
  63. Stys P. K., Ransom B. R., Waxman S. G. Effects of polyvalent cations and dihydropyridine calcium channel blockers on recovery of CNS white matter from anoxia. Neurosci. 1990; 115: 293-299.
  64. Stys P. K., Ransom B. R., Waxman S. G. et al. Role of extracellular calcium in anoxic injury of mammalian central white matter. Proc. Natl. Acad. Sci. USA, 1990, 87, 4212-4216.
  65. Stys P. K., Waxman S. G., Ransom B. R. Na+-Ca2+ exchanger mediates Ca2+ influx during anoxia in mammalian central nervous system white matter. Ann. Neurol. 1991; 30: 375- 380.
  66. Stys P. K., Waxman S. G., Ransom B. R. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na+-Ca+ exchanger. J. Neurosci. 1992; 12: 430- 439.
  67. Subhan Z., Hindmarch L. Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur. J. Clin. Pharmacol. 1985; 28: 567-571.
  68. Szakdll Sz., Boros L, Balkay L. et al. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. J. Neuroimaging 1998; 8: 197-204.
  69. Szobor A., Klein M. Ethyl apovincaminate therapy in neuro-vascular diseases. Arzneim-Forsch. (Drug. Res.) 1976; 26: 1984-1989.
  70. Tamaki N., Kusunoki T., Matsumoto S. Effect of vinpocetine on cerebral blood flow in patients with cerebrovascular disorders. Adv. Ther., 1985; 2: 53-59.
  71. Tohgi H., Sasaki K., Chiba K. et al. Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Bin-swanger type. Arzneimittelforschung 1990; 40: 640-643.
  72. Wakita H., Tomimoto H., Akiguchi L. et al. Glial activation and white matter changes in the rat brain induced by chronic cerebral hypoperfusion: an immunohistochemical study. Acta Neuropath. 1994; 87: 484-492.
  73. Waxman S. G., Black A., Stys P. K. et al. Ultrastructural concomitants of anoxic injury and early post-anoxic recovery in rat optic nerve Brain Res. 1992; 574: 105-119.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies